Invitrogen™ Rovalpituzumab Recombinant Monoclonal Antibody

Catalog No.	Quantity
MA558297	100 μg
MA558298	1 mg

Catalog No. MA558297 Supplier Invitrogen™ Supplier No. MA558297

Description

Recombinant Monoclonal Antibody

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Rovalpituzumab is a biosimilar that targets DLL3. Delta-like protein 3 (DLL3) is a ligand for the Notch signaling pathway. It inhibits primary neurogenesis. DLL3 plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. Defects in DLL3 are the cause of Spondylocostal dysostosis autosomal recessive type 1 (SCDO1). Mutations in DLL3 gene cause truncal shortening relative to their limbs, which leads to abdominal protrusion, abnormal spinal curvature and sometimes a plagiocephaly-torticollis sequence. It may be required to divert neurons along a specific differentiation pathway.

Specifications

• Antigen: Rovalpituzumab Humanized
• Applications: ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
• Classification: Recombinant Monoclonal
• Concentration: 1 mg/mL
• Conjugate: Unconjugated
• Formulation: 25mM histidine with 0.01% Tween 80, 8% sucrose and no preservative; pH 6.2
• Gene Alias: Rovalpituzumab tesirine; Rova-T
• Host Species: Human
• Purification Method: Protein A
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Lyophilized
• Isotype: IgG1 κ